SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Noven Pharmaceuticals (NOVN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John McCarthy who wrote (5)8/28/1997 10:50:00 PM
From: Todd D. Wiener   of 66
 
John-

I'm not sure I understand your question. Noven is currently marketing DentiPatch. They only began the national roll-out during Q2. Q3 and Q4 should be much better, with a continuous ramp-up over the next several quarters. Over the next several quarters, an increasing number of dentists will use the DentiPatch. Also, revenues and earnings should improve as Novartis and RPR resume buying the estrogen patches from NOVN (in Q3 & 4).

I hope I answered your question.

Todd
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News